Insight

Gautam Mehta summarizes the FDA accelerated approval of fam-trastuzumab deruxtecan-nxki for HER2-mutated NSCLC

Photo from Gautam Mehta/X

Jul 19, 2024, 22:19

Gautam Mehta summarizes the FDA accelerated approval of fam-trastuzumab deruxtecan-nxki for HER2-mutated NSCLC

FDA oncology shared on X:

“OCE’s Gautam Mehta and colleagues summarize the FDA accelerated approval of fam-trastuzumab deruxtecan-nxki—the first targeted treatment option for patients with HER2-mutated non-small cell lung cancer – via The Oncologist Journal.”

fam-trastuzumab deruxtecan-nxki

**FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations**

Autors: Gautam U Mehta, Paz J Vellanki, Yi Ren, Anup K Amatya, Pallavi S Mishra-Kalyani, Lili Pan, Jeanne F Zirkelbach, Yuzhuo Pan, Jiang Liu, Stephanie L Aungst, Claudia P Miller, Mirat Shah, Nam Atiqur Rahman, Marc Theoret, Paul Kluetz, Richard Pazdur, Julia A Beaver, Harpreet Singh

fam-trastuzumab deruxtecan-nxki

Source: FDA Oncology/X

Anup K Amatya cancer Claudia P Miller FDA Oncology Gautam Mehta Gautam U Mehta Harpreet Singh HER2 gene HER2 mutant NSCLC Jeanne F Zirkelbach Jiang Liu Julia A Beaver Lili Pan Marc Theoret Mirat Shah Nam Atiqur Rahman OncoDaily Oncology Pallavi S Mishra-Kalyani Paul Kluetz Paz J Vellanki Richard Pazdur Stephanie L Aungst The Oncologist Journal Yi Ren Yuzhuo Pan

Karen Knudsen: Better Together - Partnering to Accelerate Progress against Cancer

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

Former Disney CEO Bob Chapek Appointed Senior Adviser at SCAN Group

Special Coverage